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Background
The present study aimed at the longitudinal evaluation of
the quality of life (QoL) of Greek patients – suffering from
definite clinical multiple sclerosis (MS) – and its relation
with fatigue and depression, in a time span of two years.
Materials and methods
In the first examination (2003) seventy seven participants
(42 women and 35 men) with MS, aged 17–67 years, were
administered: a) QOLIE-89, measuring QoL and func-
tioning levels, b) BDI measuring depression and c) FIP
and FSS scales, measuring 4 dimensions of "fatigue" and
"severity of fatigue", respectively. Two years later (2005)
fifty of those patients were randomly selected and were
administered the above-mentioned tests for a second
time. Twenty six patients, who were receiving antidepres-
sants during either the first or the second evaluation, were
excluded from the reevaluation study. Eventually, the
final group consisted of twenty four patients (14 women
and 10 men), aged 20–72 years.
Results
In the first evaluation (2003), the Pearson's correlation
showed that the 4 dimensions and "severity of fatigue"
correlated (negatively) with most subscales of QOLIE-89.
Stepwise regression analysis showed that physical and
cognitive/mental fatigue predicted different aspects of MS
patients" QoL. Depression predicted health-related
aspects of QoL and in some cases added to the effects of
fatigue on QoL.
In the second evaluation (2005), according to the analy-
ses through ANOVA models, a statistically important
improvement in the general quality of life was revealed,
but no other statistically important changes concerning
the measurement of depression (BDI) and the dimen-
sions of "fatigue" and "severity of fatigue" (FIP, FSS) were
found.
Discussion
The results of our study on the negative influence of
depression and fatigue on the QoL of patients with MS are
in accordance with existing literature. Regarding the out-
comes from the follow-up examination it is noteworthy
that there were no statistically important changes in the
measurement of depression or fatigue, but there was an
important amelioration in the general quality of life. This
could be due to the two-year interval between the two
examinations or due to the acceptance, better confronta-
tion and coping with the disease and its course by the
patients.
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